Skip to main content

Brittany A Davidson, MD

Property title
Assistant Professor of Obstetrics and Gynecology
Email: brittany.davidson@duke.edu

Education and Training

  • , Duke University, 2013 - 2016
  • , University of Texas Southwestern Medical Center at Dallas Southwestern Medical School, 2009 - 2013
  • M.D., University of Virginia, 2009

Research

I have many research interests that can be most easily summarized as 'the patient experience of GYN cancer" — these range from patient preferences for treatment options in ovarian cancer, communication preferences in women with gynecologic malignancies, role of palliative care in Gyn Onc, medication compliance, use of narcotics following GYN Oncology surgeries...the list goes on. 

While we do not yet have cures for many of our gynecologic malignancies, my main research focus is improving the experience of women with GYN malignancies through improved communication strategies, understanding patient values and goals, helping to improve quality of life during and after cancer treatments. Career-wise, I am passionate about education and hope to remain in an academic environment so that I can be involved in the creation of outstanding OB/GYNs and Gynecologic Oncologists for years to come.

Publications

Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer." International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists 37, no. 3 (May 2018): 252-255.

Full Text

Davidson, BA, Moss, HA, Arquiette, J, and Kamal, AH. "Top 10 Tips Palliative Care Clinicians Should Know When Caring for Patients with Endometrial Cancer." Journal of palliative medicine (March 13, 2018).

Full Text

Davidson, BA, Moss, HA, and Kamal, AH. "Top 10 Tips Palliative Care Clinicians Should Know When Caring for Patients with Ovarian Cancer." Journal of Palliative Medicine 21, no. 2 (February 2018): 250-254.

Full Text

Makker, V, Green, AK, Wenham, RM, Mutch, D, Davidson, B, and Miller, DS. "New therapies for advanced, recurrent, and metastatic endometrial cancers." Gynecologic Oncology Research and Practice 4, no. 1 (December 2017).

Full Text

Gillen, J, Mills, KA, Dvorak, J, Zheng, B, Thai, T, Salani, R, Cosgrove, CM, Davidson, B, Thaker, PH, and Moore, KN. "Imaging Biomarkers of Adiposity and Sarcopenia as Potential Predictors for Overall Survival Among Patients with Endometrial Cancer Treated with Bevacizumab." October 2017.

Full Text

Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic Oncology 147, no. 1 (October 2017): 98-103.

Full Text

Madden-Fuentes, RJ, Koontz, BF, Harrison, MR, George, DJ, Davidson, B, Gilmore, BF, Moul, JW, Mantyh, C, and Peterson, AC. "How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies?." Oncology (Williston Park) 31, no. 4 (April 15, 2017): 286-294. (Review)

Scholars@Duke

Foote, JR, Gaillard, S, Broadwater, G, Sosa, JA, Davidson, B, Adam, MA, Secord, AA, Jones, MB, Chino, J, and Havrilesky, LJ. "Disparities in the surgical staging of high-grade endometrial cancer in the United States." Gynecologic Oncology Research and Practice 4 (January 19, 2017): 1-null.

Full Text

Davidson, BA, Foote, J, Clark, LH, Broadwater, G, Ehrisman, J, Gehrig, P, Graybill, W, Alvarez Secord, A, and Havrilesky, LJ. "Tumor grade and chemotherapy response in endometrioid endometrial cancer." Gynecologic Oncology Reports 17 (August 2016): 3-6.

Full Text

Davidson, BA, Squatrito, R, Duska, LR, Havrilesky, LJ, Schwager, N, McCollum, M, Arapovic, S, and Secord, AA. "Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma." May 20, 2016.

Full Text

Pages